ClinicalTrials.gg
WithdrawnNCT05041972Updated Sep 13, 2022

ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)

A Phase 2 interventional study of ARX788 in HER2 Mutation-Related Tumors and HER2 Amplified Solid Tumors, sponsored by Ambrx, Inc.. Withdrawn at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-13.

Sponsored by Ambrx, Inc. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Business strategy change

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Carcinoma, Non-Small-Cell Lung by Johnson & Johnson — 7 open to participants now, 18 under way, 4 of them phase 3. Carcinoma, Non-Small-Cell Lung · Johnson & Johnson.

Enrollment
27th of 28
0 · median 70
Started
2021
with 1 other
Phase 2
8 of 36
4 open now
Registered
22nd of 36
by date

Among the 36 studies in Carcinoma, Non-Small-Cell Lung by Johnson & Johnson, this one is the 27th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2021, is one of 8 in phase 2, and was the 22nd registered.

Carcinoma, Non-Small-Cell Lung

7,624 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

7 of the 36 studies in Carcinoma, Non-Small-Cell Lung by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Carcinoma, Non-Small-Cell Lung by Johnson & Johnson, or all of them as a file.
02

Study summary

A Global Phase 2 Study to Evaluate the Efficacy and Safety of ARX788 for Selected HER2-mutated or HER2-amplified/overexpressed Solid Tumors (ACE-Pan tumor-02)

Read the detailed description

The study will enroll subjects with HER2-mutated or HER2-amplified/overexpressed locally advanced or metastatic solid tumor cancers whose prior standard of care therapies have failed. This basket trial will evaluate ARX788 across multiple cancer populations, as defined by HER2 genetic biomarkers

03

Conditions studied

  • HER2 Mutation-Related Tumors
  • HER2 Amplified Solid Tumors

Keywords

  • HER2 Mutation
  • HER2 Amplification
  • Non-Small Cell Lung Cancer (NSCLC)
  • Colorectal (CRC)
  • Biliary Tract Cancer (BTC)
  • Breast Cancer
  • Other Solid Tumors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years and older
  • > 3 months
  • Eastern Cooperative Oncology Performance Status ≤ 1
  • status must be determined from a local Clinical Laboratory Improvement Amendments (CLIA) or equivalent-certified laboratory.
  • Cohort 1, Cohort 2, and Explanatory Cohort A: HER2 mutated subjects with pre-specified HER2 activating mutation. Subjects with HER2 mutations in NSCLC (Cohort 1), breast cancer (Cohort 2), and other solid tumors (Cohort A) who have not received prior HER2 antibody drug conjugate (ADC) treatment are eligible.
  • Cohort 3: Subjects with HER2 amplifications in biliary tract cancers (BTC) who have not received prior HER2 ADC treatment are eligible.
  • Cohort 4: Subjects with HER2 amplifications in colorectal cancer (CRC), ovarian, endometrial, NSCLC and other solid tumors who have not received prior HER2 ADC treatment are eligible.
  • Cohort 5 HER2 mutation or HER2 amplification: subjects with HER2 mutated or amplified tumors and have been previously treated with HER2 ADC are eligible.
  • Subjects who are resistant or to previous standard care of treatment.
  • Subjects with stable .
  • Adequate organ functions.

Exclusion criteria

Exclusion Criteria:

Any subject who meets any of the following criteria is excluded from the study:

  • For Cohort 4: breast and gastric/GEJ cancer are excluded.
  • Prior history of interstitial lung disease, pneumonitis, or other lung disease within 12 months.
  • History of ocular events, any current ongoing active ocular infections, or any chronic corneal disease unless approved by Medical Monitor.
  • Exposure to any other or commercial anticancer agents or therapies administered with the intention to treat within 14 days before the first dose of ARX788.
  • Clinically significant surgical intervention (excluding diagnostic ) within 21 days of the first dose of ARX788.
  • Radiotherapy administered less than 21 days prior to the first dose of ARX788, or localized palliative radiotherapy administered less than 7 days prior to the first dose of ARX788, or radiotherapy-induced toxicity of Grade 2 or greater based on v 5.0.

There are additional inclusion and exclusion criteria. The study center will determine if criteria for participation are met.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Cohort 1: HER2 Mutated Non-Small Cell Lung Cancer (NSCLC)

    Intervention: Drug: ARX788

    Drug: ARX788

  • Experimental
    Cohort 2: HER2 Mutation Breast Cancer

    Intervention: Drug: ARX788

    Drug: ARX788

  • Experimental
    Exploratory Cohort A: Other HER2-Mutated tumors

    Intervention: Drug: ARX788

    Drug: ARX788

  • Experimental
    Cohort 3: HER2 Amplification Biliary Tract Cancer (BTC)

    Intervention: Drug: ARX788

    Drug: ARX788

  • Experimental
    Cohort 4 HER2 Amplification Colorectal (CRC), Ovarian Endometrial, NSCLC, and other solid tumors

    Intervention: Drug: ARX788

    Drug: ARX788

  • Experimental
    Cohort 5: HER2 Mutation or HER2 Amplification Solid Tumors

    Intervention: Drug: ARX788

    Drug: ARX788

Interventions

  • DrugARX788

    ARX788 will be administered by intravenous (IV) infusion every 3 weeks (Q3W).

    Also known as: ADC

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    The confirmed objective response rate (ORR) of ARX788 by blinded independent central review (BICR) based on RECIST 1.1 in Cohorts 1-5. The ORR is defined as the number of subjects with a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the number of response evaluable subjects

    Time frame: At the end of every 2 cycles (each cycle is 21 days)

Secondary outcomes

  1. Duration of Response

    DOR is defined as the time between the date of first response and the date of disease progression or death, whichever occurs first, will be computed for subjects with a BOR of CR or PR.

    Time frame: 1 year

  2. Best Overall Response (BOR)

    BOR is defined as the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started).

    Time frame: At the end of every 2 cycles (each cycle is 21 days)

  3. Disease Control Rate (DCR)

    DCR is defined as the proportion of complete response (CR), partial response (PR), and stable disease (SD) rates.

    Time frame: 2 years

  4. Progression Free Survival (PFS)

    PFS is defined as the time between date of first dose of study therapy and date of progression or death.

    Time frame: 2 years

  5. Overall Survival (OS)

    Overall survival (OS) is defined as the time from first dose of study therapy to the date of death (any cause).

    Time frame: 2 years

  6. Time to Response (TTR)

    Time to response (TTR) is defined as the time from the start of treatment to the first objective tumor response

    Time frame: At the end of every 2 cycles (each cycle is 21 days)

  7. Maximum serum concentration (Cmax) for ARX788, total antibody, and metabolites

    Pharmacokinetic parameter maximum serum concentration (Cmax) for ARX788, total antibody, and metabolites.

    Time frame: Cycle 1 and Cycle 3

  8. Trough concentration (Ctrough) for ARX788, total antibody, and metabolites

    Pharmacokinetic parameter trough concentration (Ctrough) for ARX788, total antibody, and metabolites.

    Time frame: Cycle 1 and Cycle 3

  9. Incidence of anti-drug antibodies (ADAs)

    Incidence of anti-drug antibodies (ADAs) following intravenous administration of ARX788 in participants with HER2-mutated or HER2-amplified locally advanced or metastatic solid tumors.

    Time frame: Predose at every cycle (each cycle is 21 days)

07

Study locations

2 sites
  • Mount Sinai Medical Center
    Miami Beach, Florida 33140, United States
  • AMR Kansas City
    Kansas City, Missouri 64114, United States
08

References and documents

Individual participant data

Plan to share: No — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available after the studies for which the medicine and indication have received marketing approval in European Union (EU) and United States (US) or regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Apr 2022, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2021
First posted
Sep 13, 2021
StartActual
Nov 5, 2021
Primary completionActual
Apr 20, 2022
CompletionActual
Apr 20, 2022
Last update
Sep 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05041972
Lead sponsor
Ambrx, Inc.
Responsible party
Sponsor
First posted
Sep 13, 2021
Start date
Nov 5, 2021
Primary completion
Apr 20, 2022
Completion
Apr 20, 2022
Last update
Sep 13, 2022

Study contacts

Global Trial Lead
study director · Ambrx, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ARX788

Start the discussion